Skinvisible, Inc. SKVI
Set alert
At close · Oct 30
- YTD
- -32.26%
- 1 year
- -68.82%
- Open
- 0.1561
- Prev close
- 0.1562
- Mkt cap
- 844.08K
- Vol
- 705
- Avg vol
- 312
- EPS
- -0.20
- P/E
- 0.00
More statistics
- Low
- 0.156
- High
- 0.1561
- Earnings
- Aug 14, 2023
News
1 year ago accessnewswire.com
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection
VANCOUVER, BC AND LAS VEGAS, NV / ACCESS Newswire / September 18, 2025 / Ovation Science Inc. (CSE:OVAT)(OTC:OVATF) ("Ovation" or the "Company"), today announced an enhanced strategic partnership…
1 year ago accessnewswire.com
Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research…
2 years ago accesswire.com
Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE /…
2 years ago accesswire.com
Promising Data on Transdermal Obesity Formulations Announced by Skinvisible
Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible…
2 years ago accesswire.com
Skinvisible Expands Obesity Patent Application for Transdermal Delivery
Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an…
2 years ago accesswire.com
Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday
-
7 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Thursday